Inotuzumab ozogamicin and gemtuzumab ozogamicin can harm the liver and can block its small blood vessels (veno-occlusive disease), more often when a transplant follows. Liver blood tests are taken around each dose, a dose is delayed if they rise, and the drug is stopped if the blockage occurs. Fast weight gain, a swollen or painful tummy or yellow skin need a call to your team at once.
The reader's own unit's policy comes first. Both drugs carry calicheamicin and both US labels carry a boxed warning for hepatotoxicity including veno-occlusive disease (VOD). The figures come from the labels. Inotuzumab ozogamicin, adults (INO-VATE): VOD in 23 of 164 (14%), in 18 of the 79 who went on to a transplant (23%) and in 5 of 164 (3%) with no transplant in between, up to 56 days after the last dose; a median of 15 days after transplant. Children (ITCC-059): 8 of 53 (15%). Gemtuzumab ozogamicin with chemotherapy (ALFA-0701): 6 of 131 (5% in the US label, 4.6% in the EU SmPC), a median of 9 days after a dose (range 2 to 298); the US label counts 3 of the 6 as fatal and the EU SmPC 2.
Before inotuzumab ozogamicin: the EU SmPC contraindicates it after confirmed severe or ongoing VOD and in serious ongoing liver disease, and asks for people with a history of liver disease to be evaluated first; the US label has no contraindication and names the same groups as at increased risk. For people going on to a transplant both labels recommend 2 cycles, and a third may be considered for those without complete remission and MRD negativity after 2. The EU SmPC says conditioning with 2 alkylating agents should be avoided (VOD in 6 of 11 against 9 of 53 with one) and that transplant with bilirubin at or above the upper limit of normal (ULN) needs careful consideration (7 of 12 against 11 of 67); the US label reports both as risk factors without that instruction. A company-funded expert panel (2018) adds early transplant referral and a preventive medicine such as ursodiol for everyone exposed; neither label mentions ursodiol, and of two small retrospective studies (abstracts only) neither found a significant fall in liver toxicity overall, though one found fewer grade 3 AST rises with ursodiol and no fewer cases of VOD.
Monitoring: ALT, AST, total bilirubin and alkaline phosphatase before and after each dose of inotuzumab ozogamicin and before each dose of gemtuzumab ozogamicin, with a watch for rising bilirubin, a large or painful liver, rapid weight gain and ascites. Bilirubin alone may miss cases (both Mylotarg labels, Besponsa EU SmPC).
Hold rules. Inotuzumab ozogamicin (both labels): interrupt when bilirubin is above 1.5 times ULN and AST or ALT above 2.5 times ULN, until both recover, unless due to Gilbert's syndrome or haemolysis; stop for good if they do not recover. An interruption of 7 days or more omits the next dose, 14 days or more cuts the next cycle's total dose by 25%, and beyond 28 days stopping is considered. Gemtuzumab ozogamicin: the US label delays for bilirubin above 2 times ULN or AST or ALT above 2.5 times ULN and omits a dose delayed more than 2 days; the EU SmPC joins the two thresholds with 'and' and says to consider omitting.
If VOD occurs both drugs are stopped (inotuzumab ozogamicin permanently) and the syndrome is treated according to standard medical practice, which the labels do not define: the transplant protocol sets out diagnosis, grading, supportive care and defibrotide after a transplant. No diagnostic criteria read were written for VOD on these drugs without a transplant, and no source read for this page says defibrotide is licensed for it.
Why: The EU SmPC contraindicates the drug after confirmed severe or ongoing veno-occlusive disease and in serious ongoing liver disease such as cirrhosis or active hepatitis, and asks for the evaluation to exclude it. The US label lists no contraindication; it says these people are at increased risk of their liver disease worsening and asks that they consider the benefit and risk carefully.
“Patients with a history of liver disease should be carefully evaluated (e.g., ultrasound scan, viral hepatitis testing) prior to treatment with BESPONSA to exclude serious ongoing hepatic disease (see section 4.3).”
European Medicines Agency; marketing authorisation holder Pfizer (industry) 2026
Why: The 2018 expert panel asks for this so that the number of cycles and the conditioning can be planned around the transplant. The panel's editorial support was funded by Pfizer, the maker, and its recommendations are not graded. Neither label says when to refer.
“As soon as it is decided that a patient will be initiating InO treatment, the patient should be referred for HCT evaluation.”
Why: Both labels give the risk of veno-occlusive disease as the reason. The expert panel reports the syndrome after transplant in 8% of people given 1 cycle, 19% given 2 and 29% given more than 2. For people not going on to a transplant both labels allow up to 6 cycles.
“For patients proceeding to hematopoietic stem cell transplant (HSCT), the recommended duration of treatment with BESPONSA is 2 cycles. A third cycle may be considered for those patients who do not achieve CR or CRi and minimal residual disease (MRD) negativity after 2 cycles”
Why: This is the EU SmPC's instruction: it reports veno-occlusive disease in 6 of 11 people conditioned with 2 alkylating agents against 9 of 53 with one, and asks for benefit and risk to be weighed before the drug is given at all where such conditioning is likely to be unavoidable. The US label reports the same association (naming busulfan with other alkylating agents) without telling prescribers to avoid it. The expert panel's text says dual alkylating agents should be avoided if possible; its table lists dual alkylating agents, thiotepa, or both.
“The use of HSCT conditioning regimens containing 2 alkylating agents should be avoided.”
European Medicines Agency; marketing authorisation holder Pfizer (industry) 2026
Why: This is the EU SmPC's instruction; it reports the syndrome in 7 of 12 people with bilirubin at or above the upper limit before transplant against 11 of 67 below it. The US label names the same finding as a risk factor without this instruction.
“In patients in whom the serum bilirubin is ≥ ULN prior to HSCT, HSCT post BESPONSA treatment should only be undertaken after careful consideration of the benefit/risk.”
European Medicines Agency; marketing authorisation holder Pfizer (industry) 2026
Why: The panel gives no reason or study for this beyond preventing the syndrome, and it is ungraded opinion from a company-funded panel. Of two small retrospective studies of ursodiol with these two drugs, read as abstracts, neither found a significant fall in liver toxicity overall; one found fewer grade 3 AST rises with ursodiol and no fewer cases of veno-occlusive disease (see variants). The panel also recommends avoiding liver-toxic medicines such as azoles with high-dose alkylator conditioning, when possible.
“Finally, it is recommended that pharmacologic agents (e.g., ursodiol) be given to all patients exposed to InO to prevent VOD.”
Why: Both labels ask for this in all patients, because a rise may mean the dose has to be withheld, reduced or stopped. The EU SmPC gives the median time to raised transaminases as 29 days and to raised bilirubin as 73 days.
“In all patients, monitor liver tests, including ALT, AST, total bilirubin, and alkaline phosphatase, prior to and following each dose of BESPONSA.”
Why: Both labels ask for the four tests before each dose. The US label gives the median time from a dose to veno-occlusive disease as 9 days, with a range of 2 to 298 days.
“Assess ALT, AST, total bilirubin, and alkaline phosphatase prior to each dose of MYLOTARG.”
Why: The labels list these as the signs of veno-occlusive disease. Both Mylotarg labels and the Besponsa EU SmPC say that monitoring only bilirubin may not identify everyone at risk; the Besponsa US label does not carry that sentence. With inotuzumab ozogamicin the syndrome was reported up to 56 days after the last dose in people who had no transplant in between.
“Monitoring only total bilirubin may not identify all patients at risk of VOD. For patients who develop abnormal liver tests, more frequent monitoring of liver tests and clinical signs and symptoms of hepatotoxicity is recommended.”
Why: The expert panel says weight gain from the kidneys holding on to water and salt is one of the earliest signs of the syndrome. The two frequencies are both the panel's own, and it is an ungraded panel whose editorial support was funded by Pfizer. The labels ask for rapid weight gain to be watched for and set no schedule.
“Monitor patient weight for fluid retention daily”
Why: The US label and the EU SmPC give the same thresholds and neither states a reason beyond the liver warning. A general row of the same table interrupts treatment for any non-haematological toxicity of grade 2 or higher until it is back to grade 1 or the pre-treatment grade. A dose that has been reduced for toxicity must not be raised again.
“Interrupt dosing until recovery of total bilirubin to less than or equal to 1.5 × ULN and AST/ALT to less than or equal to 2.5 × ULN prior to each dose unless due to Gilbert's syndrome or hemolysis. Permanently discontinue treatment if total bilirubin does not recover to less than or equal to 1.5 × ULN or AST/ALT does not recover to less than or equal to 2.5 × ULN”
Why: The US label and the EU SmPC print the same table. If a further change is needed after the 25% cut, the number of doses falls to 2 a cycle, and if that is not tolerated the drug is stopped for good. Neither label gives a reason for the steps.
“Once adequate recovery is achieved, decrease the total dose by 25% for the subsequent cycle. If further dose modification is required, then reduce the number of doses to 2 per cycle for subsequent cycles.”
Why: The two labels differ. The US label delays when bilirubin is above 2 times the limit or AST or ALT is above 2.5 times it, and says to omit the delayed dose. The EU SmPC's table joins the two thresholds with 'and' and says to consider omitting the dose. Neither gives a reason beyond the liver warning.
“Delay treatment with MYLOTARG until recovery of total bilirubin to less than or equal to 2 × ULN and AST and ALT to less than or equal to 2.5 × ULN prior to each dose.”
Why: The expert panel regards everyone given inotuzumab ozogamicin as at high risk and asks for close monitoring to allow early diagnosis and treatment. It leaves further tests such as abdominal ultrasound, hepatic venous pressure measurement and transjugular liver biopsy to the physician's discretion. The diagnostic criteria themselves are on the transplant page.
“Unexpected weight changes and/or changes in liver function should alert the physician to the possibility of VOD and should lead to further diagnostic workup before further treatment with InO.”
Why: Both labels say so; the US label says it in its boxed warning. Its dose table gives the same instruction for other severe liver toxicity. Of the 18 cases after transplant in INO-VATE, 5 were fatal.
“Permanently discontinue treatment if VOD occurs. If severe VOD occurs, treat according to standard medical practice”
Why: Both labels say so, in almost the same words. Neither label says what standard practice is, and neither mentions defibrotide; the transplant page sets out supportive care and defibrotide for the syndrome after a transplant.
“In patients who experience VOD, discontinue MYLOTARG and treat according to standard medical practice.”
Why: The expert panel says this in the paragraph where it follows the EBMT position statement of 2015, which it says makes supportive care the first step. The panel adds that mild disease should be followed closely because the severity grade can change rapidly. It describes defibrotide as the only agent approved in the United States and European Union for veno-occlusive disease with renal or pulmonary compromise, and does not say whether that covers the syndrome arising without a transplant; the labels of these two drugs do not mention defibrotide, and no source read for this page says it is licensed outside a transplant. The transplant page gives the defibrotide labels' indications. A task force commissioned by EBMT published a separate position statement on prevention and treatment in adults in 2020, written for the syndrome after a transplant.
“Careful attention to fluid balance is recommended for all patients regardless of VOD severity.”
Why: The US label gives the median time from transplant to the syndrome as 15 days, with a range of 3 to 57 days. The EU SmPC says 'closely' during the first month and gives no interval. For gemtuzumab ozogamicin the US label says to monitor liver tests frequently after a transplant, as appropriate.
“For patients who proceed to HSCT, monitor liver tests at least weekly during the first month post-HSCT, then less frequently thereafter, according to standard medical practice.”
Why: The Besponsa US label asks prescribers to tell patients this; the Mylotarg US label asks them to tell patients that the signs of liver toxicity should be monitored regularly, without the words on seeking advice. The EU package leaflets say to tell the doctor immediately (Besponsa) or right away (Mylotarg) and add pain in the upper right side of the abdomen. Macmillan tells people on inotuzumab ozogamicin to contact the hospital straight away on the 24-hour number.
“Inform patients that they should seek immediate medical advice if they experience symptoms of VOD, which may include elevated bilirubin, rapid weight gain, and abdominal swelling that may be painful.”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
The dose rules are the labels', and for each drug the US and EU labels are shown side by side because they are not identical. For inotuzumab ozogamicin they agree on the tests (before and after each dose), the hold thresholds (bilirubin above 1.5 times and AST or ALT above 2.5 times the upper limit of normal), stopping for good if veno-occlusive disease occurs, and 2 cycles before a transplant with a third to be considered. They differ in that only the EU SmPC contraindicates the drug after severe or ongoing veno-occlusive disease and in serious liver disease, says dual-alkylator conditioning should be avoided, and asks for careful consideration before a transplant with raised bilirubin; only the US label sets weekly liver tests for the first month after transplant. For gemtuzumab ozogamicin they agree on tests before each dose and on discontinuing for veno-occlusive disease; the US label delays for a bilirubin or a transaminase rise and omits a dose delayed over 2 days, where the EU SmPC's table joins the thresholds with 'and' and says to consider omitting. No graded guideline that could be read addresses the liver risk of these two drugs outside a transplant. The fullest management advice is a 2018 expert panel review whose editorial support was funded by Pfizer; it is ungraded, covers inotuzumab ozogamicin only, and adds early transplant referral, daily weights, avoiding thiotepa (in its table) and liver-toxic drugs with conditioning, and ursodiol for everyone exposed. Ursodiol is unproven with these drugs: of two small retrospective studies, read as abstracts, neither found a significant fall in liver toxicity overall, though one found fewer grade 3 AST rises with it and no fewer cases of veno-occlusive disease. Defibrotide to prevent the syndrome after these drugs is also unsettled (variants). The ELN 2024 and ESMO 2024 guidance on ALL could not be read.
Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2026 · European Medicines Agency; marketing authorisation holder Pfizer (industry) 2026 · Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2025 · European Medicines Agency; marketing authorisation holder Pfizer (industry) 2025 · Bone Marrow Transplantation (Kebriaei et al.). Industry-funded: editorial support paid for by Pfizer, the maker of inotuzumab ozogamicin 2018 · Journal of Oncology Pharmacy Practice (Mosallam et al.; 2026, volume 32, issue 5; first online January 2025) 2026 · Journal of Oncology Pharmacy Practice (Sabatino et al.; 2023, volume 29, issue 4; first online March 2022) 2023
Where it differs: Contraindications: the EU SmPC lists prior confirmed severe or ongoing veno-occlusive disease and serious ongoing hepatic disease (for example cirrhosis, nodular regenerative hyperplasia, active hepatitis); the US label says "None". Conditioning: the EU SmPC says regimens with 2 alkylating agents should be avoided; the US label reports them as significantly associated with the syndrome. Bilirubin at or above the upper limit before transplant: the EU SmPC asks for careful consideration of benefit and risk; the US label lists it as a risk factor. Monitoring after transplant: the US label says liver tests at least weekly in the first month; the EU SmPC says closely. Bilirubin alone: only the EU SmPC warns that it may not identify all patients at risk. Age: the EU SmPC lists age 65 or over among the subgroups in which veno-occlusive disease after transplant was reported in half or more, and age 55 or over as an associated factor; the US label says increased age. Earlier transplant: the EU SmPC asks for careful consideration before the drug is given to someone who has had a transplant.
Evidence: Both rest on the INO-VATE trial (164 adults given the drug) and, for children, the ITCC-059 study (53 children). Same in both: 2 cycles before a transplant with a third to be considered; liver tests before and after each dose; the hold thresholds; permanent discontinuation for veno-occlusive disease or other severe liver toxicity; the table of dose changes by length of interruption. The US text read is version 8 on DailyMed (effective 6 February 2026); the EU product information is the version the EMA lists as last updated 18 May 2026.
Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2026 · European Medicines Agency; marketing authorisation holder Pfizer (industry) 2026
Where it differs: Hold threshold: the US table reads total bilirubin above 2 times the upper limit, or AST and/or ALT above 2.5 times it; the EU table reads total bilirubin above 2 times and AST and/or ALT above 2.5 times. Delayed dose: the US label says to omit a scheduled dose delayed more than 2 days between sequential infusions; the EU SmPC says to consider omitting it. Deaths from veno-occlusive disease in ALFA-0701: the US label says three of the 6 events were fatal, the EU SmPC that 2 were. Who is treated: the US label covers newly diagnosed disease from 1 month of age and relapsed or refractory disease from 2 years; the EU licence is for previously untreated disease from 15 years, with daunorubicin and cytarabine.
Evidence: Same in both: liver tests before each dose; discontinuation for veno-occlusive disease, treated according to standard medical practice; the statement that bilirubin alone may not identify all patients at risk; and the risk analysis in adults given the drug alone at higher doses (8.7 times the risk with moderate or severe liver impairment beforehand, 2.6 times with a transplant before the drug, 2.9 times with a transplant after it). The US text read is version 19 on DailyMed (effective 19 December 2025); the EU product information is the version the EMA lists as last updated 17 September 2025.
Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2025 · European Medicines Agency; marketing authorisation holder Pfizer (industry) 2025
Where it differs: The 2018 expert panel recommends a preventive medicine such as ursodiol for everyone exposed to inotuzumab ozogamicin, and says people who develop the syndrome should continue it. Neither drug's US label or EU SmPC mentions ursodiol. The position statement of the task force commissioned by EBMT (2020) recommends ursodeoxycholic acid from the start of conditioning to day 90 after a transplant in adults, and the British guideline (2013) suggests it for prophylaxis (2C); both are written for transplants, not for these drugs given without one.
Evidence: The panel cites no study for the recommendation, and its editorial support was funded by Pfizer. Two retrospective studies have looked at it with these drugs, both read as abstracts only. In 82 adults given either drug outside a transplant (Mosallam 2026, first online January 2025), 87.8% had ursodiol; the authors concluded it "is not associated with lower incidences of hepatotoxicity, SOS/VOD, or time to Grade 3 AST transaminitis, but is associated with decreased incidence of AST elevations"; grade 3 AST rises were 20.8% with ursodiol against 60% without (p = 0.015), and the syndrome occurred in 3 patients, all given ursodiol (4.2% against 0%, not significant). The study excluded people who went on to a transplant. In 49 patients (Sabatino 2023, first online March 2022), liver toxicity occurred in 2 of 14 (14%) with ursodiol and 15 of 35 (43%) without (p=0.10), and after adjustment ursodiol did not significantly reduce it; the abstract does not report veno-occlusive disease. No randomised trial was found.
Bone Marrow Transplantation (Kebriaei et al.). Industry-funded: editorial support paid for by Pfizer, the maker of inotuzumab ozogamicin 2018 · Journal of Oncology Pharmacy Practice (Mosallam et al.; 2026, volume 32, issue 5; first online January 2025) 2026 · Journal of Oncology Pharmacy Practice (Sabatino et al.; 2023, volume 29, issue 4; first online March 2022) 2023 · A global task force commissioned by EBMT (Bone Marrow Transplantation, Mohty et al.; 2020, first online October 2019). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) to the association that funded the work; all authors declared honoraria or research support from Jazz 2020 · British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 · Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2026 · Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2025
Where it differs: Gives defibrotide from conditioning in people who have had one of these drugs. The British guideline (2013) names prior gemtuzumab ozogamicin among the risk factors for which it recommends defibrotide prophylaxis in children (1A) and suggests it in adults (2B) having an allogeneic transplant; it does not name inotuzumab ozogamicin. The EBMT-commissioned task force (2020) says prophylaxis can be considered in adults at very high risk, defined by at least two major risk factors, of which previous gemtuzumab ozogamicin or inotuzumab ozogamicin is one. Neither drug's label mentions defibrotide.
Evidence: EBMT's Handbook (2024) reports that a randomised trial in 372 children and adults at high risk found no significant difference in survival free of the syndrome at day 30 (67% with defibrotide, 73% with best supportive care). The same chapter reports an earlier randomised trial in 360 high-risk children in which defibrotide cut the incidence from 20% to 12% (p = 0.049), and says the evidence on prophylaxis "seems to be contradictory". After inotuzumab ozogamicin the evidence is small and retrospective. In seven adults given defibrotide and ursodeoxycholic acid (Giglio 2022), the syndrome occurred in 3 and was fatal in all 3; all three had a second alkylating agent in their conditioning. In one children's centre (Paolino 2026), it occurred in 4 of 26 (15%) given defibrotide prophylaxis after inotuzumab ozogamicin and 3 of 6 (50%) not given it; one author declared honoraria from the maker of defibrotide. In the ITCC-059 paediatric trial (Iannicelli 2026, funded by Pfizer), where prophylaxis followed each centre's own guidelines, it "did not appear to reduce SOS incidence". The EBMT statement had an educational grant from the maker of defibrotide. The transplant page gives the regulators' position.
British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 · A global task force commissioned by EBMT (Bone Marrow Transplantation, Mohty et al.; 2020, first online October 2019). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) to the association that funded the work; all authors declared honoraria or research support from Jazz 2020 · EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024 · Frontiers in Oncology (Giglio et al.). A single-centre series of seven adults; no commercial ties declared 2022 · Blood Advances (Paolino et al.). Single-centre retrospective study; one author declared honoraria from Jazz Pharmaceuticals (industry) 2026 · HemaSphere (Iannicelli et al.). Sponsored by Erasmus MC and funded by Pfizer (industry) 2026
Where it differs: No label sets an interval as its own rule. Both Mylotarg labels report that the ALFA-0701 study recommended 2 months between the last dose and a transplant, although no relationship (US label; "no definitive relationship" in the EU SmPC) was found between the timing of a transplant and the syndrome in the analysis of higher single-agent doses. For inotuzumab ozogamicin the labels give no interval. The EBMT Handbook's chapter on adult ALL says the transplant should be scheduled ideally within 6 to 8 weeks after the start of salvage therapy. The ITCC-059 authors suggest an interval of 35 days or more from the last dose when disease control permits.
Evidence: ITCC-059 (children; 60 transplanted within 6 months of the last dose, 14 cases): a transplant within 35 days of the last dose was associated with more veno-occlusive disease (odds ratio 3.6, 95% CI 1.02 to 13.08), borderline in the exploratory multivariable model; the authors ask for confirmation in larger cohorts. A Spanish retrospective study of 107 adolescents and adults (abstract only) found an interval of 50 days or less independently associated with the syndrome (hazard ratio 3.15). The 2020 task force statement says a specific warning is recommended when a transplant is planned shortly after inotuzumab ozogamicin.
Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2025 · European Medicines Agency; marketing authorisation holder Pfizer (industry) 2025 · EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024 · HemaSphere (Iannicelli et al.). Sponsored by Erasmus MC and funded by Pfizer (industry) 2026 · Transplantation and Cellular Therapy (Balaguer-Roselló et al., for the Spanish transplant group GETH-TC) 2026 · A global task force commissioned by EBMT (Bone Marrow Transplantation, Mohty et al.; 2020, first online October 2019). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) to the association that funded the work; all authors declared honoraria or research support from Jazz 2020
Where it differs: US label: conditioning with 2 alkylating agents is significantly associated with an increased risk (no instruction). EU SmPC: such regimens "should be avoided". Expert panel (2018): regimens containing dual alkylating agents "should be avoided if possible" in its text; its table says to avoid regimens containing dual alkylating agents, thiotepa, or both. EBMT Handbook, adult ALL chapter (2024): conditioning associated with significant toxicities such as veno-occlusive disease "must be avoided" after inotuzumab ozogamicin.
Evidence: INO-VATE, as the EU SmPC reports it: the syndrome in 6 of 11 (55%) people conditioned with 2 alkylating agents and 9 of 53 (17%) with one. The panel says dual alkylators were a risk factor on multivariate analysis in that trial. In ITCC-059 conditioning did not reach statistical significance as a risk factor, which its authors put down to the small number of events.
Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2026 · European Medicines Agency; marketing authorisation holder Pfizer (industry) 2026 · Bone Marrow Transplantation (Kebriaei et al.). Industry-funded: editorial support paid for by Pfizer, the maker of inotuzumab ozogamicin 2018 · EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024 · HemaSphere (Iannicelli et al.). Sponsored by Erasmus MC and funded by Pfizer (industry) 2026
Where it differs: The labels of both drugs say only to treat according to standard medical practice. The expert panel on inotuzumab ozogamicin refers to the EBMT position statement of 2015 and describes defibrotide as the only agent approved in the United States and European Union for the syndrome with renal or pulmonary compromise; it does not say whether that covers the syndrome arising without a transplant, and no source read for this page says defibrotide is licensed for it. A literature analysis looked at defibrotide in people who developed the syndrome after gemtuzumab ozogamicin.
Evidence: Richardson and Corbacioglu (2020): across the studies found, 27 of 248 people (11%) exposed to gemtuzumab ozogamicin developed the syndrome and were given defibrotide, and treatment was called successful (survival, response or both, as each study defined it) in 17 of 27 (63%); 20 of the 27 came from one dose-finding study after transplant, in which 10 (50%) were alive at day 100 after the transplant. The work was supported by Jazz Pharmaceuticals, the maker of defibrotide, which also paid for medical writing, and both authors declared ties to it. Doses, the licensed indications and bleeding precautions are on the transplant page.
Blood Cancer Journal (Richardson and Corbacioglu). Supported by Jazz Pharmaceuticals (industry), which also funded medical writing 2020 · Bone Marrow Transplantation (Kebriaei et al.). Industry-funded: editorial support paid for by Pfizer, the maker of inotuzumab ozogamicin 2018 · Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2026 · Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2025
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Inotuzumab ozogamicin: 2 cycles for people going on to a transplant; a third may be considered “Due to the risk of VOD/SOS, for patients proceeding to HSCT, the recommended duration of treatment with inotuzumab ozogamicin is 2 cycles; a third cycle may be considered for those patients who do not achieve a CR or CRi and MRD negativity after 2 cycles (see section 4.2).” | Regulatory label; not graded | European Medicines Agency; marketing authorisation holder Pfizer (industry) 2026 |
| Inotuzumab ozogamicin is contraindicated in the EU after confirmed severe or ongoing veno-occlusive disease “Patients who have experienced prior confirmed severe or ongoing venoocclusive liver disease/sinusoidal obstruction syndrome (VOD/SOS).” | Regulatory label (EU SmPC section 4.3); not graded | European Medicines Agency; marketing authorisation holder Pfizer (industry) 2026 |
| Inotuzumab ozogamicin: veno-occlusive disease or other severe liver toxicity ends treatment “Treatment should be permanently discontinued if VOD/SOS occurs (see section 4.2).” | Regulatory label; not graded | European Medicines Agency; marketing authorisation holder Pfizer (industry) 2026 |
| Inotuzumab ozogamicin: the US label reports dual-alkylator conditioning and bilirubin at or above the upper limit before transplant as risk factors, without an instruction to avoid “The risk of VOD was greater in patients who underwent HSCT after BESPONSA treatment; use of HSCT conditioning regimens containing 2 alkylating agents and last total bilirubin level ≥ upper limit of normal (ULN) before HSCT were significantly associated with an increased risk of VOD.” | Regulatory label (boxed warning); not graded | Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2026 |
| Gemtuzumab ozogamicin: monitor frequently for veno-occlusive disease after treatment “Monitor frequently for signs and symptoms of VOD after treatment with MYLOTARG.” | Regulatory label (boxed warning); not graded | Wyeth Pharmaceuticals, a subsidiary of Pfizer (industry), on DailyMed, US National Library of Medicine 2025 |
| Gemtuzumab ozogamicin: the EU SmPC says to consider omitting a dose delayed more than 2 days, where the US label says to omit it “Consider omitting scheduled dose if delayed more than 2 days between sequential infusions.” | Regulatory label; not graded | European Medicines Agency; marketing authorisation holder Pfizer (industry) 2025 |
| Gemtuzumab ozogamicin: the ALFA-0701 study's 2-month interval before transplant is reported, not adopted as a rule “No definitive relationship was found between VOD and time of HSCT relative to higher MYLOTARG monotherapy doses, however, the ALFA-0701 study recommended an interval of 2 months between the last dose of MYLOTARG and HSCT.” | Regulatory label; not graded | European Medicines Agency; marketing authorisation holder Pfizer (industry) 2025 |
| Limit inotuzumab ozogamicin to 2 cycles, if feasible, when a transplant is considered “In patients for whom HCT is considered, the number of InO cycles should be limited to 2, if feasible, because the rate of VOD increases with increasing cycles of InO” | Expert panel opinion (ungraded; editorial support funded by Pfizer) | Bone Marrow Transplantation (Kebriaei et al.). Industry-funded: editorial support paid for by Pfizer, the maker of inotuzumab ozogamicin 2018 |
| Avoid dual-alkylator conditioning after inotuzumab ozogamicin if possible “In addition, conditioning regimens containing dual alkylating agents (e.g., thiotepa and melphalan) should be avoided if possible, because the use of dual alkylator regimens was identified as a risk factor for developing VOD based on multivariate analysis findings in the INO-VATE study” | Expert panel opinion (ungraded; editorial support funded by Pfizer) | Bone Marrow Transplantation (Kebriaei et al.). Industry-funded: editorial support paid for by Pfizer, the maker of inotuzumab ozogamicin 2018 |
| Ursodiol or another preventive medicine for everyone exposed to inotuzumab ozogamicin “Finally, it is recommended that pharmacologic agents (e.g., ursodiol) be given to all patients exposed to InO to prevent VOD.” | Expert panel opinion (ungraded; editorial support funded by Pfizer) | Bone Marrow Transplantation (Kebriaei et al.). Industry-funded: editorial support paid for by Pfizer, the maker of inotuzumab ozogamicin 2018 |
| Ursodeoxycholic acid for prophylaxis of veno-occlusive disease (written for transplants; these drugs are not named) “Ursodeoxycholic acid is suggested for use in the prophylaxis of VOD (SOS) (2C).” | 2C | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Defibrotide prophylaxis in children having an allogeneic transplant with risk factors that include prior gemtuzumab ozogamicin “Defibrotide is recommended at a dose of 6.25 mg/kg intravenously four times daily for the prevention of VOD (SOS) in children undergoing allogeneic stem cell transplantation with the following risk factors: pre-existing hepatic disease, second myeloablative transplant, allogeneic transplant for leukaemia beyond second relapse, conditioning with busulfan-containing regimens, prior treatment with gemtuzumab ozogamicin, diagnosis of primary haemophagocytic lymphohistiocytosis, adrenoleucodystrophy or osteopetrosis (1A).” | 1A | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Defibrotide prophylaxis in adults having an allogeneic transplant with the same risk factors, including prior gemtuzumab ozogamicin “Defibrotide is suggested at a dose of 6.25 mg/kg intravenously four times daily for the prevention of VOD (SOS) in adults undergoing allogeneic stem cell transplantation with the following risk factors: pre-existing hepatic disease, second myeloablative transplant, allogeneic transplant for leukaemia beyond second relapse, conditioning with busulfan-containing regimens, prior treatment with gemtuzumab ozogamicin, diagnosis of primary haemophagocytic lymphohistiocytosis, adrenoleucodystrophy or osteopetrosis (2B).” | 2B | British Committee for Standards in Haematology and British Society for Blood and Marrow Transplantation (British Journal of Haematology, Dignan et al.) 2013 |
| Defibrotide prophylaxis can be considered in adults at very high risk, where previous gemtuzumab or inotuzumab ozogamicin counts as one major risk factor “DF prophylaxis can be considered in adult patients at very high risk of SOS/VOD.” | Expert position of a task force commissioned by EBMT (ungraded; educational grant from Jazz Pharmaceuticals) | A global task force commissioned by EBMT (Bone Marrow Transplantation, Mohty et al.; 2020, first online October 2019). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) to the association that funded the work; all authors declared honoraria or research support from Jazz 2020 |
| A specific warning when an allogeneic transplant is planned shortly after inotuzumab ozogamicin “In particular, specific warning is recommended when allo-HCT is planned shortly after inotuzumab ozogamicin salvage treatment for relapsed ALL.” | Expert position of a task force commissioned by EBMT (ungraded; educational grant from Jazz Pharmaceuticals) | A global task force commissioned by EBMT (Bone Marrow Transplantation, Mohty et al.; 2020, first online October 2019). Supported by an unrestricted educational grant from Jazz Pharmaceuticals (industry) to the association that funded the work; all authors declared honoraria or research support from Jazz 2020 |
| After inotuzumab ozogamicin, conditioning associated with veno-occlusive disease must be avoided “Moreover, conditioning therapies associated with significant toxicities (e.g., SOS/VOD for patients treated with inotuzumab ozogamicin) must be avoided.” | Handbook chapter (ungraded) | EBMT (Springer; Sureda, Corbacioglu, Greco, Kröger and Carreras, editors). A handbook of expert chapters, not a graded guideline 2024 |
| Ursodiol with these two drugs outside a transplant was not associated with less liver toxicity or veno-occlusive disease, but was associated with fewer AST rises “In our cohort, ursodiol prophylaxis in adults receiving GO/InO is not associated with lower incidences of hepatotoxicity, SOS/VOD, or time to Grade 3 AST transaminitis, but is associated with decreased incidence of AST elevations.” | Retrospective cohort, 82 adults (abstract) | Journal of Oncology Pharmacy Practice (Mosallam et al.; 2026, volume 32, issue 5; first online January 2025) 2026 |
Shares Veno-occlusive disease of the liver (sinusoidal obstruction syndrome) after stem cell transplant: prevention, monitoring, diagnosis and defibrotide, Conditioning regimen (myeloablative, reduced-intensity), Stem cell transplant: conditioning, the low blood count phase and engraftment monitoring, Allogeneic stem cell transplantation.
Shares Caution: inotuzumab before transplant (veno-occlusive disease), Inotuzumab ozogamicin, Allogeneic stem cell transplantation.
Shares Defibrotide, Veno-occlusive disease of the liver (sinusoidal obstruction syndrome) after stem cell transplant: prevention, monitoring, diagnosis and defibrotide.
Shares Hepatic dose adjustment of anticancer drugs in reduced liver function, Hepatotoxicity (liver enzyme elevation).
Shares Conditioning regimen (myeloablative, reduced-intensity), Stem cell transplant: conditioning, the low blood count phase and engraftment monitoring, Allogeneic stem cell transplantation.